Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies 3 commercial products with strong growth in revenues and margins. 4 MIN READ 08.30.2017
As Sam Sees It: A Refresher on the Rules of Wall Street Each week, we tap the insight of Sam Stovall, Chief Equity Strategist for S&P Capital IQ, for his perspective on the current market.EQ: With 2012 getting underway, we thought it would be a 7 MIN READ 01.19.2012
